Search Results - "Elverdi, T."

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey by Salihoglu, A., Elverdi, T., Karadogan, I., Paydas, S., Ozdemir, E., Erdem, G., Karadurmus, N., Akyol, G., Kaynar, L., Yegin, ZA, Sucak, G., Ozkocaman, V., Topcuoglu, P., Ozcan, M., Birtas, E., Goker, H., Baslar, Z., Ferhanoglu, B.

“…Current treatment modalities can cure up to 70–80 % of patients with classical Hodgkin lymphoma. Approximately, 20–30 % of patients require further treatment…”
Get full text

PB1899: DEVELOPMENT AND VALIDATION OF A PREDICTIVE SCORING SYSTEM FOR THE PROGNOSIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE RECEIVING FIRST‐LINE IMATINIB by Bektaş, M., Eşkazan, A. E., Tiryaki, T. O., Mullai, R., Elverdi, T., Salihoğlu, A., Tiribelli, M., Ar, M. C., Öngören, S., Başlar, Z., Nalçaci, M., Soysal, T.

Get full text

Carfilzomib in Relapsed/Refractory Multiple Myeloma, Single Center Experience by Aydin, Y, Erdogan, I, Salihoglu, A, Elverdi, T, Yalniz, F.F, Berk, S, Sadri, S, Keskin, D, Eskazan, A.E, Ar, M.C, Ongoren, S, Baslar, Z, Soysal, T

Get full text

IgD Multiple Myeloma, Descriptive Report of Eight Cases, Single Centre Experience by Ongoren, S, Erdogan, I, Salihoglu, A, Elverdi, T, Yalniz, F.F, Berk, S, Sadri, S, Keskin, D, Yurttas, N.O, Eskazan, A.E, Ar, M.C, Baslar, Z, Soysal, T, Aydin, Y

Get full text

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura by Elverdi, Tugrul, Eskazan, Ahmet Emre

“…Thrombotic thrombocytopenic purpura (TTP) is a rare disease with a mortality rate of over 90% if left untreated. Therapeutic plasma exchange (PEX) is the…”
Get full text

Treatment Responses, Toxicity, and Survival in Patients with Classical Hodgkin Lymphoma Aged ≥50 Years: A Single-Center Experience Over Two Decades by Çokgezer, Simay, Elverdi, Tuğrul, Salihoğlu, Ayşe, Ar, Muhlis Cem, Öngören, Şeniz, Başlar, Zafer, Eşkazan, Ahmet Emre

“…The aim of this study was to evaluate treatment responses, toxicity, and survival among cHL patients aged ≥50 years. We retrospectively identified all newly…”
Get full text

PB1904 PROPHYLAXIS FOR OCCULT HBV INFECTION UNDER IBRUTINIB THERAPY: MANDATORY OR OPTIONAL? by Ercaliskan, A., Eskazan, A.E., Salihoglu, A., Keskin, D., Ozmen, D., Elverdi, T., Ar, M.C., Soysal, T.

“…Background: Ibrutinib is a Bruton's tyrosine kinase inhibitor which plays a critical role in the management of some B cell malignancies. Although there are…”
Get full text

PB1929 POTENTIAL DRUG‐DRUG INTERACTIONS AMONG PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TYROSINE KINASE INHIBITOR THERAPY WITH IMATINIB by Kunbaz, A., Eskazan, A.E., Ozmen, D., Sasmaz, A., Hakmi, A., Shahab, S., Elverdi, T., Salihoglu, A., Ar, M.C., Soysal, T.

“…Background: The introduction of imatinib (IM) has revolutionized the treatment of chronic myeloid leukemia (CML). CML patients (pts) achieving optimal…”
Get full text

Tuberculosis After Hematopoietic Stem Cell Transplantation: Retrospective Study of Infectious Diseases Working Party EBMT by Drozd-Sokolowska, J, Tridello, G, Kozijn, AE, Karakukcu, M, Ben Abdeljelil, N, Kroger, N, Passweg, J, Aljurf, M, Colita, A, Atay, D, Tanase, A, Vazquez, L, Piekarska, A, Faraci, M, Elverdi, T, Carlson, K, McQuaker, G, Snowden, JA, Labussiere-Wallet, H, Patrick, K, Jindra, P, Al Zahrani, M, Bolaman, Z, Waszczuk-Gajda, A, Baurmann, H, Krivan, G, Broers, AEC, Blennow, O, Basak, GW, Knelange, N, Averbuch, D, Gil, L, Mikulska, M, Styczynski, J

Get full text